A triple-blinded, randomized, placebo-controlled trial to examine the efficacy of buspirone added to typical antipsychotic drugs in patients with chronic schizophrenia

A triple-blinded, randomized, placebo-controlled trial to examine the efficacy of buspirone added to typical antipsychotic drugs in patients with chronic schizophrenia

Background: The purpose of this study was to test the hypothesis that the addition of buspirone, a partial agonist of 5HT1A receptor, to ongoing treatment with typical antipsychotics would improve the positive and negative symptoms in patients with chronic schizophrenia. Materials and Methods: In th...

Full description

Bibliographic Details
Main Authors: Fatemeh Sheikhmoonesi, Mehran Zarghami, Seyyedeh Fatemeh Bahari Saravi, Alireza Khalilian, Shahram Ala
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2015-01-01
Series:Journal of Research in Medical Sciences
Subjects:
5HT1A
buspirone
chronic schizophrenia
Online Access:http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2015;volume=20;issue=2;spage=140;epage=145;aulast=Sheikhmoonesi

Internet

http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2015;volume=20;issue=2;spage=140;epage=145;aulast=Sheikhmoonesi

Similar Items